CAR T-cell therapy for multiple myeloma gained approval in 2017, so it’s still in its infancy. Data on efficacy and long-term safety are limited due to the short time frame and small numbers of ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

Multiple myeloma can cause high calcium levels and low ... It can show areas of bone loss from multiple myeloma. An MRI, which uses powerful magnets and radio waves to make three ... (CAR) T-cell ...

Mailankody et al. demonstrate that Target 2 CAR T therapy can effectively treat multiple myeloma. If Target 1 CAR T therapy fails, Target 2 appears to be a viable alternative.

CAR T cell therapy is a novel therapy that doctors might use to treat difficult cases of multiple myeloma. It is effective but has many side effects associated with it. Learn more here.

Number one is, given the high degree of efficacy that the CAR T cells have, there's a great interest in knowing should we really be waiting for giving these CAR T cells to patients with relapse and ...

Investigators describe these findings as the longest reported follow-up for CAR-T therapy in multiple myeloma to date and interpret them as evidence of potentially curative outcomes in a subset ...

There are currently two FDA-approved CAR T cell products for multiple myeloma: Ide-cel and cilta-cel. Ide-cel impressively decreases signs of multiple myeloma in 72% of patients, and cilta-cel 98% ...

What Diamantis’ Treatment Was Like With Allogenic Car T Cells for Multiple Myeloma Two weeks after completing screening assessments, Diamantis began receiving the allogeneic CAR T cells. He stayed at ...

Multiple myeloma, a rare blood cancer, now has many treatment options.; A new CAR T cell therapy targeting an antigen called GPRC5D appears to be safe and effective.; For people with multiple myeloma, ...

Magnetic resonance imaging ... Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med 2019;11(485):eaau7746-eaau7746.

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, ...